Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib

EBioMedicine

Volumn 2, Issue 4, 2015, Pages 351-355

  Jabbari, Ali ^a   Dai, Zhenpeng ^a   Xing, Luzhou ^a   Cerise, Jane E ^a   Ramot, Yuval ^b   Berkun, Yackov ^b   Sanchez, Gina A Montealegre ^c   Goldbach Mansky, Raphaela ^c   Christiano, Angela M ^a   Clynes, Raphael ^a   Zlotogorski, Abraham ^b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

Alopecia areata; Autoimmune disease; Autoinflammatory; Baricitinib; CANDLE syndrome; Gene expression profiling; Interferon gamma; JAK inhibitor

Indexed keywords

BARICITINIB; CORTICOSTEROID; INTERFERON; JANUS KINASE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PLACEBO; STAT1 PROTEIN; AZETIDINE DERIVATIVE; JANUS KINASE; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

ALOPECIA AREATA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANDLE SYNDROME; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FLOW CYTOMETRY; HAIR GROWTH; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; METABOLIC DISORDER; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SCORING SYSTEM; SKIN BIOPSY; ANIMAL; ANTAGONISTS AND INHIBITORS; C3H MOUSE; DISEASE MODEL; ENZYMOLOGY; METABOLISM;

ALOPECIA AREATA; ANIMALS; AZETIDINES; DISEASE MODELS, ANIMAL; INTERFERONS; JANUS KINASES; MALE; MICE, INBRED C3H; PROTEIN KINASE INHIBITORS; SULFONAMIDES;

EID: 84949643647     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.02.015     Document Type: Article

References (18)

1. Agarwal A.K., Xing C., DeMartino G.N., et al. PSMB8 encoding the β5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome. Am. J. Hum. Genet. 2010, 87:866-872.
2. Arima K., Kinoshita A., Mishima H., et al. Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:14914-14919.
3. Betz R.C., Petukhova L., Ripke S., et al. Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci. Nat. Commun. 2015, 6:5966. 10.1038/ncomms6966.
4. Craiglow B.G., King B.A. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J. Investig. Dermatol. 2014, 134:2988-2990.
5. Finner A.M. Alopecia areata: clinical presentation, diagnosis, and unusual cases. Dermatol. Ther. 2011, 24:348-354.
6. Fleischmann R., Kremer J., Cush J., et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N. Engl. J. Med. 2012, 367:495-507.
7. Freyschmidt Paul P., McElwee K.J., Hoffmann R., et al. Interferon-γ-deficient mice are resistant to the development of alopecia areata. Br. J. Dermatol. 2006, 155:515-521.
8. Genovese M.C., Keystone E., Taylor P., et al. 24-Week results of a blinded phase 2b dose-ranging study of baricitinib, an oral Janus kinase 1/Januse kinase 2 inhibitor, in combination with traditional disease modifying antirheumatic drugs in patients with rheumatoid arthritis 2012, 64:S1049-S1050.
9. Ghoreishi M., Martinka M., Dutz J.P. Type 1 interferon signature in the scalp lesions of alopecia areata. Br. J. Dermatol. 2010, 163:57-62.
10. Liu Y., Ramot Y., Torrelo A., et al. Mutations in proteasome subunit β type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. Arthritis Rheum. 2012, 64:895-907.
11. Petukhova L., Duvic M., Hordinsky M., et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature 2010, 466:113-117.
12. Pieri L., Guglielmelli P., Vannucchi A.M. Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia. Am. J. Hematol. 2015, 90:82-83.
13. Ports W.C., Khan S., Lan S., et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br. J. Dermatol. 2013, 169:137-145.
14. Punwani N., Scherle P., Flores R., et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J. Am. Acad. Dermatol. 2012, 67:658-664.
15. Ramot Y., Czarnowicki T., Maly A., Navon Elkan P., Zlotogorski A. Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature syndrome: a case report. Pediatr. Dermatol. 2011, 28:538-541.
16. Torrelo A., Patel S., Colmenero I., et al. Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome. J. Am. Acad. Dermatol. 2010, 62:489-495.
17. Verstovsek S., Kantarjian H., Mesa R.A., et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N. Engl. J. Med. 2010, 363:1117-1127.
18. Xing L., Dai Z., Jabbari A., et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat. Med. 2014, 20:1043-1049.